| Assessment Status | Rapid Review Complete |
| HTA ID | 26036a |
| Drug | Cemiplimab |
| Brand | Libtayo® |
| Indication | Cemiplimab is indicated as a monotherapy for the first-line treatment of adult patients with non-small-cell lung cancer expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: • Locally advanced non-small-cell lung cancer and are not candidates for definitive chemoradiation; or • Metastatic non-small-cell lung cancer Regeneron |
| Assessment Process | |
| Rapid review commissioned | 10/07/2026 |
| Rapid review completed | 14/08/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that cemiplimab (Libtayo®) not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here